Overview
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:
- What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?
- What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?
Participants will:
Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Eligibility
Inclusion Criteria:
- Patients with clinical diagnosis of brain tumor;
- Be at least 18 years old;
- The final pathological results could be obtained by surgery or biopsy;
- Informed consent and the ability to be followed up;
- Those who did not meet the exclusion criteria.
Exclusion Criteria:
- Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before 99mTc-CNDG injection;
- Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
- Severe hypersensitivity or hypersensitivity to radiocontrast agents;
- Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
- Patients receiving radiotherapy and chemotherapy;
- Being pregnant or breastfeeding.